AdaptHealth (NASDAQ:AHCO) Director David Solomon Williams III Sells 5,000 Shares of Stock

AdaptHealth Corp. (NASDAQ:AHCO) Director David Solomon Williams III sold 5,000 shares of AdaptHealth stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $9.43, for a total transaction of $47,150.00. Following the completion of the sale, the director owned 45,045 shares of the company’s stock, valued at $424,774.35. This represents a 9.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

AdaptHealth Stock Up 0.4%

Shares of AdaptHealth stock opened at $9.42 on Friday. The company has a market cap of $1.28 billion, a price-to-earnings ratio of 17.13, a price-to-earnings-growth ratio of 1.38 and a beta of 1.77. The company’s 50 day moving average is $9.32 and its 200 day moving average is $9.21. AdaptHealth Corp. has a twelve month low of $7.11 and a twelve month high of $11.63. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 1.09.

AdaptHealth (NASDAQ:AHCO) last posted its earnings results on Tuesday, November 4th. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.05). The company had revenue of $820.31 million during the quarter, compared to the consensus estimate of $799.62 million. AdaptHealth had a return on equity of 4.85% and a net margin of 2.53%.The company’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same period last year, the firm posted $0.15 EPS. Research analysts anticipate that AdaptHealth Corp. will post 0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

AHCO has been the topic of a number of recent research reports. Zacks Research downgraded AdaptHealth from a “hold” rating to a “strong sell” rating in a report on Friday, September 19th. Canaccord Genuity Group upped their price target on shares of AdaptHealth from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of AdaptHealth in a research note on Tuesday. Finally, Wall Street Zen downgraded shares of AdaptHealth from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.60.

Institutional Trading of AdaptHealth

A number of hedge funds and other institutional investors have recently bought and sold shares of AHCO. Cetera Investment Advisers purchased a new position in shares of AdaptHealth during the 1st quarter valued at about $208,000. XTX Topco Ltd bought a new stake in AdaptHealth during the 1st quarter worth approximately $468,000. New Age Alpha Advisors LLC bought a new stake in AdaptHealth during the 1st quarter worth approximately $2,503,000. Charles Schwab Investment Management Inc. lifted its holdings in AdaptHealth by 14.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,301,652 shares of the company’s stock valued at $14,110,000 after purchasing an additional 163,272 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of AdaptHealth in the first quarter worth approximately $4,358,000. Hedge funds and other institutional investors own 82.67% of the company’s stock.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.